CYP2C9 Ile359Leu polymorphism, plasma irbesartan concentration and acute blood pressure reductions in response to irbesartan treatment in Chinese hypertensive patients

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 28, Issue 1, 2006, Pages 19-24

  Chen, G ^a,b   Jiang, S ^a,c   Mao, G ^a   Zhang, S ^c   Hong, X ^a,c   Tang, G ^a   Li, Z ^a   Liu, X ^a   Zhang, Y ^d   Xing, H ^a   Wang, B ^a   Yu, Y ^a,c   Xu, Xiping ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b ANHUI UNIVERSITY OF CHINESE MEDICINE   (China)

^c UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^d PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Blood pressure; CYP2C9 gene; Drug concentration; Gene polymorphism; Irbesartan; Pharmacogenetics

Indexed keywords

CYTOCHROME P450 2C9; IRBESARTAN; LEUCINE;

ADULT; ARTICLE; BLOOD PRESSURE; CHINA; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG SAFETY; FEMALE; FLUORESCENCE; FOLLOW UP; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; QUESTIONNAIRE; SYSTOLIC BLOOD PRESSURE; VENOUS BLOOD;

ADMINISTRATION, ORAL; ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ARYL HYDROCARBON HYDROXYLASES; BIPHENYL COMPOUNDS; BLOOD PRESSURE; CHINA; FEMALE; GENOTYPE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, GENETIC; QUESTIONNAIRES; TETRAZOLES;

EID: 33645375097     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2006.28.1.962773     Document Type: Article

References (25)

1. Cazaubon, C.J., Gougat, F., Bousquet, P. et al. Pharmacological characterization of SR 47436, a new nonpeptide AT1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther 1993, 265: 826-34.
2. Reeves, R.A., Lin, C.S., Kassler-Taub, K., Pouleur, H. Dose-related efficacy of irbesartan for hypertension: An integrated analysis. Hypertension 1998, 31: 1311-6.
3. Markham, A.S.C., Jarvis, B. Irbesartan: An updated review of its use in cardiovascular disorders. Drugs 2000, 59: 1187-206.
4. Taavitsainen, P., Kiukaanniemi, K., Pelkonen, O. In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists. Eur J Clin Pharmacol 2000, 56: 135-40.
5. Bourrie, M., Meunier, V., Berger, Y., Fabre, G. Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes. Drug Metab Dispos 1999, 27: 288-96.
6. Shu, Y., Cheng, Z.N., Liu, Z.Q. et al. Interindividual variations in levels and activities of cytochrome P-450 in liver microsomes of Chinese subjects. Acta Pharmacol Sin 2001, 22: 283-8.
7. Steward, D.J., Haining, R.L., Henne, K.R. et al. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 1997, 7: 361-7.
8. Aithal, G.P., Day, C.P., Kesteven, P.J., Daly, A.K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999, 353: 717-9.
9. Haining, R.L., Hunter, A.P., Veronese, M.E., Trager, W.F., Rettie, A.E. Allelic variants of human cytochrome P450 2C9: Baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys 1996, 333: 447-58.
10. Crespi, C.L., Miller, V.P. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH: Cytochrome P450 oxidoreductase. Pharmacogenetics 1997, 7: 203-10.
11. Kimura, M., Ieiri, I., Mamiya, K., Urae, A., Higuchi, S. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther Drug Monit 1998, 20: 243-7.
12. Hallberg, P., Karlsson, J., Kurland, L. et al. The CYP2C9 genotype predicts the blood pressure response to irbesartan: Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. J Hypertens 2002, 20: 2089-93.
13. Hong, X., Zhang, S., Mao, G. et al. CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population. Eur J Clin Pharmacol 2005, 61: 627-34.
14. Liu, L., He, G.W., Yan, Q., Shi, A.X., Li, K.X., Sun, C.H. Studies on the pharmacokinetics and bioequivalence of domestic irbesartan tablet in healthy volunteers. Chinese Pharm J 2002, 37: 123-5.
15. Gillis, J.C., Markham, A. Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs 1997, 54: 885-902.
16. Pouleur, H.G. Clinical overview of irbesartan: A new angiotensin Il receptor antagonist. Am J Hypertens 1997, 10: 318S-24S.
17. Sullivan-Klose, T.H., Ghanayem, B.I., Bell, D.A. et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996, 6: 341-9.
18. Niu, T., Struk, B., Lindpaintner, K. Statistical considerations for genome-wide scans: Design and application of a novel software package POLYMORPHISM. Hum Hered 2001, 52: 102-9.
19. Leung, A.Y., Chow, H.C., Kwong, Y.L. et al. Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients. Blood 2001, 98: 2584-67.
20. Yang, J.Q., Morin, S., Verstuyft, C. et al. Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations. Fundam Clin Pharmacol 2003, 17: 373-6.
21. Yoon, Y.R., Shon, J.H., Kim, M.K. et al. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br J Clin Pharmacol 2001, 51: 277-80.
22. Ruilope, L. Human pharmacokinetic/pharmacodynamic profile of irbesartan: A new potent angiotensin II receptor antagonist. J Hypertens Suppl 1997, 15: S15-S20.
23. Takanashi, K., Tainaka, H., Kobayashi, K., Yasumori, T., Hosakawa, M., Chiba, K. CYP2C9 Ile359 and Leu359 variants: Enzyme kinetic study with seven substrates. Pharmacogenetics 2000, 10: 95-104.
24. Babaoglu, M.O., Yasar, U., Sandberg, M. et al. CYP2C9 genetic variants and losartan oxidation in a Turkish population. Eur J Clin Pharmacol 2004, 60: 337-42.
25. Sekino, K., Kubota, T., Okada, Y. et al. Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects. Eur J Clin Pharmacol 2003, 59: 589-92.